32 results about "Premedication" patented technology

Using betaKlotho or a substance that increases or inhibits betaKlotho activity as an agent for controlling the activity of FGF21 mediated by an FGF receptor, the present invention provides a pharmaceutical composition comprising such betaKlotho or such substance as an active ingredient, particularly, a pharmaceutical composition for anti-metabolic syndrome, and further particularly, a pharmaceutical composition for therapeutic or preventive use associated with the control of blood glucose level. In addition, the present invention provides a screening system for each of a substance that enhances or suppresses betaKlotho activity, an FGF21-like active substance, and a betaKlotho-like active substance, which uses a cell system that has expressed an FGF receptor and / or betaKlotho on the surface thereof.

The present invention is a system and method that produces features and indices that indicate the presence or absence of a disease or condition, or of the progression of a disease or condition. The system and method of the present invention also produce features and indices that predict responsiveness to medication from a premedication baseline. The system and method of the present invention further incorporates a testing methodology to improve the performance characteristics of the features or indices. To obtain such features and indices, time domain, power spectrum, bispectrum and higher order spectrum values are derived from biopotential signals taken from the subject being tested.

A method for treating, ameliorating or preventing the onset of anxiety in a subject comprises administering to such subject an NMDA receptor antagonist in an amount that is sub-anesthetic and hypo-analgetic. The NMDA receptor antagonist may comprise ketamine and its pharmaceutically acceptable salts, and is administered as a premedication. Instances of use in this manner include administration prior to an anxiety causing event, such as a medical or a dental procedure. The administration of the NMDA receptor antagonist composition is particularly useful as a premedication for adults.

The invention discloses a lactobacillus vaginal capsule and a preparation method thereof. The prepared lactobacillus vaginal capsule is a powdered capsule composed of excipient and living enterostreptococcus, wherein one capsule contains at least 2.5 million strains per gram of living enterostreptococcus; and the excipient comprises calcium carbonate powder and medicinal starch in a ratio of 1:1. The experiments show that the lactobacillus vaginal capsule can fully supplement lactobacillus which is the most important material in vagina so as to inhibit the growth and propagation of bacteria and play the action of using bacteria to inhibit bacteria; the best advantage of the lactobacillus vaginal capsule is to overcome the problem that the abuse of antibiotics and related products results in that vaginitis repeatedly relapses so as to cause microecological imbalance, drug resistance, superinfection, side effect and the like, solve the problem that patients have symptoms but can not find pathogeny and the problems such as overdiagnosis, over-treatment and medication security of lactation and pregnant women, provide a new choice for prophylactic of healthy women and fill the blank of the medication for lactation and pregnant women.

The purpose in this invention is to providing drugs for treating or preventing duplication of hypertension with serum hyperuricemia and / or hypercholesterolemia that is much frequency among the duplication onset in geriatric diseases. This invention is related to drugs for treating or preventing duplication of hypertension with serum hyperuricemia and / or hypercholesterolemia of which active principles are 2-propyl-3- {[2'-(1H-tetrazole -5-yl) biphenyl -4-yl]methyl}-5, 6, 7, 8-tetrahydrocyclohepta imidazole -4-(3H) - one and that prodrug or that salt. Pratosartan is able to use in combination with one or more than two diuretics chosen from sulfonamide-, phenoxyacetic acid- and thiazide-type diuretics, triamterene, amiloride, spironolactone, potassium canrenoate and traxanox sodium. Also, pratosartan is able to use in combination with one or more than two hypolipidemic drugs chosen from statins, fibrates, cholesterol absorption inhibitors, cholesterol sequestrants and cholesterol excretion enhancers.

The invention relates to a Chinese medical composition for treating hepatitis and a preparation method thereof. The composition is prepared by traditional Chinese medicines according to the following parts by weight: 30-70 parts of fructus schisandrae, 20-50 parts of radix bupleuri, 8-20 parts of mahonia, 6-20 parts of medlar, 5-20 parts of angelica sinensis, 5-15 parts of salvia miltiorrhiza, 5-10 parts of liquorice and 5-10 parts of radix paeoniae alba. The Chinese medical composition is used for treating and preventing hepatitis for patients, and is reasonable in formula by adopting characteristic ethnomedicine formula theories and treatment principles, and safe and effective by using pure Chinese medicines for treating the hepatitis.

The invention relates to a composition for improving treating or preventing constipation comprising Cassia fermented by lactic acid bacteria as an active ingredient and a preparation method thereof. The Cassia fermented by lactic acid bacteria can used for a long time, is high in safety, and is low in side effect when be used as a crude drug. The Cassia fermented by lactic acid bacteria has an effect that more than one of the excrement amount, the moisture content and the excrement weight is increased, the effect is the same as that of a commercial Dulcolax-S with sennoside or bisacodyl and docusate sodium as the active ingredient, the commercial Dulcolax-S is an irritant constipation therapeutic agent and is forbidden to be used for health care foods due to the side effect. Thus, the Cassia fermented by lactic acid bacteria can be applied to pharmaceutical compositions for constipation treatment or prevention, or health care foods for constipation improvement or prevention. Furthermore, the Lactobacilluskefiri MJ90 bacterial strain is beneficial to the preparation of Cassia fermented by lactic acid bacteria for improving treating or preventing constipation.

Using betaKlotho or a substance that increases or inhibits betaKlotho activity as an agent for controlling the activity of FGF21 mediated by an FGF receptor, the present invention provides a pharmaceutical composition comprising such betaKlotho or such substance as an active ingredient, particularly, a pharmaceutical composition for anti-metabolic syndrome, and further particularly, a pharmaceutical composition for therapeutic or preventive use associated with the control of blood glucose level. In addition, the present invention provides a screening system for each of a substance that enhances or suppresses betaKlotho activity, an FGF21-like active substance, and a betaKlotho-like active substance, which uses a cell system that has expressed an FGF receptor and / or betaKlotho on the surface thereof.

The present invention relates to methods of direct pulmonary delivery of polypeptides e.g. of domain antibodies, and to particular polypeptide compositions suitable for direct pulmonary delivery. The invention also relates to use of such compositions in medicine, e.g. for the treatment and diagnosis of lung disease, for example for treating Chronic Obstructive Pulmonary Disease (COPD) and asthma.

Disclosed is a compound useful as an active ingredient for medicines having PDE4B inhibiting activity, in particular, therapeutic or preventive medicinal compositions for schizophrenia, Alzheimer's disease, dementia, depression and the like. Specifically, the present inventors examined compounds having PDE4B inhibiting activity and found that a tricyclic or tetracyclic imidazo[1,2-a]pyridine derivative or salts thereof had superior PDE4B inhibiting activity. This imidazo[1,2-a]pyridine derivative can be used in therapeutic and preventative agents for schizophrenia, Alzheimer's disease, dementia, depression, and the like.

The present invention identifies a cancer antigen protein which is expressed specifically on the surface of a cancer cell, and provides a use of an antibody, which targets the cancer antigen protein, as a therapeutic and / or prophylactic agent for cancer. Specifically disclosed is a pharmaceutical composition for the treatment and / or prevention of cancer, which is characterized by containing, as an active ingredient, an antibody that is immunologically reactive with a partial polypeptide of CAPRIN-1 represented by the even-numbered sequences of SEQ ID NOS: 2-30, said partial polypeptide comprising the amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having 80% or more sequence identity to the amino acid sequence, or a fragment of the antibody.

A method for treating, ameliorating or preventing the onset of anxiety in a subject comprises administering to such subject an NMDA receptor antagonist in an amount that is sub-anesthetic and hypo-analgetic. The NMDA receptor antagonist may comprise ketamine and its pharmaceutically acceptable salts, and is administered as a premedication. Instances of use in this manner include administration prior to an anxiety causing event, such as a medical or a dental procedure. The administration of the NMDA receptor antagonist composition is particularly useful as a premedication for adults.

The invention discloses a backache relieving capsule for treating backache and a preparation method thereof. According to different traditional Chinese medicine characteristics, ephedra stem, pawpaw, herba epimedii, radix angelicae pubescentis, notopterygium root, bark of eucommia, rhizoma cibotii, clematis root, achyranthes root, licorice root, dragon's blood, prepared semen strychni, prepared bitter orange, ground beetle, scorpion, pseudo-ginseng, muscardine silkworm and colchicine as raw materials are respectively subjected to processing and extraction, the extraction products are blended according to a certain ratio, and the mixture is processed to form the capsules. Through combination of Chinese and western medicines, the backache relieving capsule has effects of strengthening muscles and bones, relaxing muscles and stimulating blood circulation, and dispersing blood stasis and relieving pain. The backache relieving capsule is used for treating lassitude in loin and legs and limb numbness caused by protrusion of lumbar intervertebral disc, sciatica and lumbar muscle degeneration, can fast promote nucleus pulposus water loss shrinking and fast elimination of tissue edema around a nerve root, realizes double effects and simultaneous treatment of principal and subordinate symptoms, and innovates a very convenient, safe and economic oral premedication treatment method for treating lumbar disc herniation.

The present invention is Mailuoning oral liquid and its application in pharmaceutical. The Mailuoning oral liquid is prepared with four kinds of Chinese medicinal materials including achyranthes root, figwort, dendrobium stem and honeysuckle, and through water extraction, filtering, concentration; alcohol precipitation to obtain supernatant, recovering alcohol, concentration; alcohol precipitation to obtain supernatant, recovering alcohol, adding water, cold storage, filtering, adding corrective and co-solvent, regulating pH value, filtering, adding water into the filtrate, regulating solution concentration, packing and serilizing. The present invention also discloses the application of Mailuoning oral liquid in preparing medicine for preventing and treating angina pectoris. The medicine for preventing and treating angina pectoris has determined curative effect, lasting and mild effect and stable quality.

The invention relates to an application of a daphniphyllum calycinum benth and red-knees herb composition in preparing a medicament for preventing and treating rheumatic diseases. The invention is characterized in that during preparing the medicament for preventing and treating the rheumatic diseases, an adopted effective constituent is prepared from the following traditional Chinese medicine raw materials in parts by weight: 1-9 parts of daphniphyllum calycinum benth and 1-9 parts of red-knees herb. The medicament prepared by the application has definite curative effect for preventing and treating the rheumatic diseases, durable action and no obvious side effect and better solves the problems of treatment drugs and prevention drugs for the rheumatic diseases.

The present invention identifies a cancer antigen protein which is expressed specifically on the surface of a cancer cell, and provides a use of an antibody, which targets the cancer antigen protein, as a therapeutic and / or prophylactic agent for cancer. Specifically disclosed is a pharmaceutical composition for the treatment and / or prevention of cancer, which is characterized by containing, as an active ingredient, an antibody that is immunologically reactive with a partial polypeptide of CAPRIN-1 represented by the even-numbered sequences of SEQ ID NOS: 2-30, said partial polypeptide comprising the amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having 80% or more sequence identity to the amino acid sequence, or a fragment of the antibody.

The present invention provides an effective method for inhibiting antro-duodenal motility in healthy subjects and patients suffering from various disorders, without the side effects associated with other pharmaceutical compositions. GLP-1 slows antro-duodenal motility and may be used for the treatment or prevention of gastrointestinal disorders such as diarrhea, postoperative dumping syndrome and irritable bowel syndrome, and also premedication in endoscopic procedures.

The purpose in this invention is to providing drugs for treating or preventing duplication of hypertension with serum hyperuricemia and / or hypercholesterolemia that is much frequency among the duplication onset in geriatric diseases. This invention is related to drugs for treating or preventing duplication of hypertension with serum hyperuricemia and / or hypercholesterolemia of which active principles are 2-propyl-3- {[2'-(1H-tetrazole -5-yl) biphenyl -4-yl]methyl}-5, 6, 7, 8-tetrahydrocyclohepta imidazole -4-(3H) - one and that prodrug or that salt. Pratosartan is able to use in combination with one or more than two diuretics chosen from sulfonamide-, phenoxyacetic acid- and thiazide-type diuretics, triamterene, amiloride, spironolactone, potassium canrenoate and traxanox sodium. Also, pratosartan is able to use in combination with one or more than two hypolipidemic drugs chosen from statins, fibrates, cholesterol absorption inhibitors, cholesterol sequestrants and cholesterol excretion enhancers.

The present invention relates to a novel nasal spray containing an aqueous solution or a fluid with an anxiolytic or anticonvulsant substance, wherein the nasal spray is characterized in that with the nasal spray, two sprays with each an equivalent, defined volume of the aqueous solution or liquid of the active agent, can be intranasally administered to a patient and wherein the nasal spray allows for an administration, independent of the spatial orientation of the nasal spray in any position of the patient (standing upright, sitting, lying or in any intermediate position). The nasal spray can be used directly without prior activation. Preferably it is apparent from the nasal spray whether a spray or even a second spray has been made with the nasal spray. Preferably, a spray of the nasal spray can be administered one-handed by the patient or a third person. The active agent in the inventive nasal spray is a benzodiazepine or a GABA-receptor agonist, preferably midazolam or a derivative thereof or a salt of these active agents. The nasal spray according to the present invention may be used for sedation, premedication or treatment of patients with claustrophobia, anxiety disorders or panic attacks or for the treatment of convulsions in CNS diseases, particularly in epileptic seizures or other manifestations of seizures (e.g. febrile convulsions). The invention also relates to a method for hermetically sealing an active agent container for use in supplying an nasal spray in accordance with the invention. The invention also relates to a method of detection by localizing the locally precise administration of an active agent in nasal application, as well as a nasal spray, preferably a bi-dose nasal spray, for which, using the cited method of detection, it has been shown both visually (qualitatively) and quantitatively that an orientation-independent, uniform and locally precise administration of the dose of the active agent onto the nasal mucosa of a patient can be achieved. Also provided is a method for airless and air-tight sealing of an active agent container in accordance with the invention.

The present invention provides an antibody targeting a cancer antigen protein specifically expressed on the surface of cancer cells and its use as a therapeutic and / or preventive agent for cancer. Specifically, it provides an antibody containing the amino acid sequence shown in SEQ ID NO: 5. or an antibody or fragment thereof that is immunoreactive with the CAPRIN-1 partial polypeptide of the amino acid sequence having 80% or more sequence identity with the amino acid sequence; Pharmaceutical composition for treatment and / or prophylaxis.

The invention discloses a preventive medicine applied before an elective orthopedic surgery. According to the prescription, the medicine consists of 10-30 parts of arenicola cristata, 15-25 parts of cladosiphon okamuranus, 5-15 parts of lentinus lepideus fr, 5-15 parts of longleaf bastardtoadflax herb, 6-10 parts of laportea violacea gaghep, 3-10 parts of pineapple peels, 6-12 parts of moellendorf's spidemoss herb, 3-10 parts of pyropolyporus formentarius teng, 6-12 parts of herb of elsholtzia rugulosa hemsl, 2-5 parts of swamp currant, 1-3 parts of codariocalyx motorius and 1-3 parts of eurya hebeclados. The medicine disclosed by the invention is reasonable in prescription and concrete in curative effect, and the medicine can be used for effectively preventing un-healed wounds in patients with diabetics in the orthopedic surgery.

[Problem] Provided is a compound which is useful as an agent for treating or preventing 5-HT 2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. [Means for Solution] The present inventors have investigated compounds having a 5-HT 2C receptor agonist activity, which is promising as an active ingredient of a pharmaceutical composition for treating or preventing incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like, and have found that the benzazepine compounds of the present invention have an excellent 5-HT 2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT 2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT 2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.

A traditional Chinese medicine composition for preventing and treating rheumatic disease is characterized in that: active components of the traditional Chinese medicine composition are made from the following traditional Chinese medicine raw materials according to the weight proportion: 1-9 parts of daphniphyllum calycinum benth and 1-9 parts of ciderage. The traditional Chinese medicine composition has outstanding curative effects on rheumatic disease prevention and treatment, long-lasting effect and no obvious side effect, and successfully solves the problems of respective drugs for preventing and treating the rheumatic disease.

The present invention discloses an antibody that targets a cancer antigen protein expressed specifically on the surface of cancer cells, and the application of the antibody in a treatment and / or preventative agent for said cancer. Specifically disclosed are: an antibody or a fragment thereof, said antibody being immunologically reactive with a partial polypeptide of CAPRIN-1 comprising the amino acid sequence represented by SEQ ID NO: 5 or an amino acid sequence having 80% or more sequence identity to the amino acid sequence represented by SEQ ID NO: 5; and a pharmaceutical composition for the treatment and / or prevention of cancer, said pharmaceutical composition being characterized by containing, as an active ingredient, the antibody or a fragment thereof.

The invention discloses a method for targeted application of ultrasound fiberoptic bronchoscopic tumor body, which comprises the following steps: firstly, local anesthesia with medication before operation, and the airway is explored according to a conventional fiberoptic bronchoscopy method to understand the location and growth of the lesion; Conventional fiberoptic bronchoscopic high-frequency electric snare and nitrogen sub-knife equipment are used to resect the tumor in the trachea; the conventional fiberoptic bronchoscope is withdrawn, and the ultrasonic bronchoscope is sent into the airway, and the ultrasonic probe detects the depth of tumor invasion into the trachea and the root and The relationship between the surrounding tissues; under the guidance of the ultrasound bronchoscope, the chemotherapy drugs cisplatin and cetuximab were injected at multiple points in the submucosal part of the tumor tissue; the ultrasound bronchoscope was withdrawn, and the conventional bronchoscope was sent into the airway again, And multi-point freezing treatment was given to the tumor site; after freezing treatment, dexamethasone and gentamicin were sprayed locally at the opening of the main bronchus on the side of the tumor lesion.

According to the present invention, a cancer antigen protein to be specifically expressed on the surfaces of cancer cells is identified and thus the use of an antibody targeting the cancer antigen protein as an agent for treating and / or preventing a cancer is provided. Specifically, the present invention provides a pharmaceutical composition for treating and / or preventing a cancer, which comprises an antibody or a fragment thereof as an active ingredient having immunological reactivity with a partial polypeptide of CAPRIN-1, wherein CAPRIN-1 is represented by any of the even-numbered sequences of SEQ ID NOS: 2 to 30, and wherein the partial polypeptide comprises the amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence.

The present invention identifies a cancer antigen protein specifically expressed on the surface of cancer cells, and uses an antibody targeting the cancer antigen protein as a therapeutic and / or preventive agent for cancer. Specifically, the present invention provides a drug for cancer A pharmaceutical composition for treatment and / or prevention, characterized in that it contains as an active ingredient an antibody or fragment thereof that is immunoreactive with a partial polypeptide of CAPRIN‑1 represented by an even-numbered sequence number in sequence numbers 2 to 30, said The partial polypeptide of CAPRIN-1 has the amino acid sequence shown in SEQ ID NO: 37, or an amino acid sequence having 80% or more sequence identity with the amino acid sequence.

The present invention provides pharmaceutical compositions for the treatment or prevention of various cardiovascular diseases, which have soluble guanylate cyclase (sGC) activation and are based on improvement of cGMP signaling. The imidazo[1,2-a]pyridine skeleton represented by the formula (I) having a carbamoyl group at the 3-position and a specific ring group bonded via a methyleneoxy group at the 8-position was found. 2-a] Pyridine compound or its salt has sGC activation effect, as the treatment or prevention of sGC-related various cardiovascular diseases, especially peripheral arterial disease, intermittent claudication, severe lower extremity ischemia, hypertension and pulmonary hypertension The present invention was accomplished by using the active ingredient of the pharmaceutical composition to be useful. (where, A 1 is a cyclohexyl group, a phenyl group substituted with 1 to 3 Fs, or a 3-fluoropyridin-2-yl group; R is a group represented by any one of the following formulae (i) to (vii). )

The invention discloses a backache relieving capsule for treating backache and a preparation method thereof. According to different traditional Chinese medicine characteristics, ephedra stem, pawpaw, herba epimedii, radix angelicae pubescentis, notopterygium root, bark of eucommia, rhizoma cibotii, clematis root, achyranthes root, licorice root, dragon's blood, prepared semen strychni, prepared bitter orange, ground beetle, scorpion, pseudo-ginseng, muscardine silkworm and colchicine as raw materials are respectively subjected to processing and extraction, the extraction products are blended according to a certain ratio, and the mixture is processed to form the capsules. Through combination of Chinese and western medicines, the backache relieving capsule has effects of strengthening muscles and bones, relaxing muscles and stimulating blood circulation, and dispersing blood stasis and relieving pain. The backache relieving capsule is used for treating lassitude in loin and legs and limb numbness caused by protrusion of lumbar intervertebral disc, sciatica and lumbar muscle degeneration, can fast promote nucleus pulposus water loss shrinking and fast elimination of tissue edema around a nerve root, realizes double effects and simultaneous treatment of principal and subordinate symptoms, and innovates a very convenient, safe and economic oral premedication treatment method for treating lumbar disc herniation.